RESUMEN
Nucleic acids are versatile materials capable of forming smart nanocarriers with highly controllable therapeutic delivery. DNA-gated release is a mechanism by which DNA oligonucleotides physically block the release of encapsulated drugs from porous nanoparticles. We extend this mechanism to be used with drugs bound to the surface of DNA-capped gold nanoparticles (AuNPs). We investigated DNA monolayers of different thicknesses and hybridization states to determine how DNA surface architecture can affect the release of a template drug bound to the gold surface. DNA layers are investigated on the planar gold surface via quartz crystal microbalance with dissipation and on AuNPs via dynamic light scattering. The resultant layer architectures were studied for their effect on the release rate of drugs. We observed that varying DNA architectures on AuNPs result in different release rates of the drug. The rate of drug release can be slowed using either folded or randomly coiled DNA sequences, which act as a physical barrier to diffusion. DNA monolayers with upright orientation release drugs more quickly. When the longer single-stranded DNA is used, the drug release is slowed even further. However, even upright DNA layers provide a barrier to drug diffusion at longer sequence lengths. We hypothesize that it is the architecture of the DNA layer, influenced by the folded or upright orientation of individual DNA molecules, that affects the free diffusion of the drug away from the AuNP surface. This mechanism may improve the biological availability of many surface-bound drugs on solid, DNA-capped nanoparticles.
Asunto(s)
Nanopartículas del Metal , Ácidos Nucleicos , Oro/química , Nanopartículas del Metal/química , Hibridación de Ácido Nucleico , Tecnicas de Microbalanza del Cristal de CuarzoRESUMEN
Over the past half century, contact lenses have been investigated for their potential as drug delivery devices for ocular therapeutics. Hundreds of studies have been published in the pursuit of the most effective and efficient release strategies and methods for contact lens drug delivery. This paper provides a thorough overview of the various contact lens drug delivery strategies, with a specific, comprehensive focus on in vivo studies that have been published since the field began in 1965. Significant accomplishments, current trends, as well as future strategies and directions are highlighted. In vivo study analysis provides a straightforward perspective and assessment of method success and commercialization potential in comparison to benchtop, in vitro studies. Analysis of the majority of published work indicates in vitro and in vivo studies do not correlate with a correlation coefficient of 0.25, with many in vitro studies grossly overestimating drug release duration and not showing appreciable drug release control. However, there has been an increase in activity in the last decade, and some methods have generated promising results exhibiting controlled release with commercialization potential. Clinical translation of drug releasing lenses is on the horizon and has high potential to impact a large number of patients providing efficacious treatment compared to current topical treatments.
RESUMEN
Purpose: The present study aimed to determine the dose-response relationship between targeted nanocarriers released from a novel, sustained release formulation and their ability to specifically deplete cells responsible for the development of posterior capsular opacification (PCO) in month-long, dynamic cell cultures. Methods: Injectable, thermosensitive poly(D,L-lactic-co-glycolic acid)-b-poly(ethylene glycol)-b-poly(D,L-lactic-co-glycolic acid) triblock copolymer hydrogels were loaded with either a low or a high dose of doxorubicin-loaded antibody-targeted nanocarriers (G8:3DNA:Dox). Human rhabdomyosarcoma cells, selected for their expression of PCO marker brain-specific angiogenesis inhibitor 1 (BAI1), were kept under dynamic media flow and received either a low or high dose of nanocarriers. Cells were fixed and stained at predetermined time points to evaluate targeted depletion of BAI1+ cells. Results: A lower dose of nanocarriers in hydrogel depleted BAI1+ cells at a slower rate than the higher dose, whereas both reached over 90% BAI1+ cellular nonviability at 28 days. Both treatment groups also significantly lowered the relative abundance of BAI1+ cells in the population compared with the control group. Conclusions: Controlled release of a lower dose of nanocarriers can still achieve therapeutically relevant effects in the prevention of PCO, while avoiding potential secondary effects associated with the administration of a higher dose.
RESUMEN
Research of nanoscale nucleic acid carriers has garnered attention in recent years due to their distinctive and controllable properties. However, current knowledge is limited in how we can efficiently utilize these systems for clinical applications. Several researchers have pioneered new and innovative nanocarrier drug delivery systems, but understanding physiochemical properties and behavior in vivo is vital to implementing them as clinical drug delivery platforms. In this review, we outline the most significant innovations in the synthesis, physical properties, and utilization of nucleic acid nanocarriers in the past 5 years, addressing the crucial properties which improve nanocarrier characteristics, delivery, and drug release. The challenges of controlling the transport of nucleic acid nanocarriers and therapeutic release for biological applications are outlined. Barriers which inhibit effective transport into tissue are discussed with emphasis on the modifications needed to overcome such obstacles. The novel strategies discussed in this work summarize the pivotal features of modern nucleic nanocarriers and postulate where future developments could revolutionize the translation of these tools into a clinical setting.
Asunto(s)
Portadores de Fármacos , Ácidos Nucleicos , Portadores de Fármacos/química , Sistemas de Liberación de Medicamentos , Liberación de FármacosRESUMEN
This study details the formation and characterisation of a novel nicotinamide adenine dinucleotide (NAD+)-associated polymeric nanoparticle system. The development of a polyelectrolyte complex (PEC) composed of two natural polyelectrolytes, hyaluronic acid and poly(L-lysine), and an evaluation of its suitability for NAD+ ocular delivery, primarily based on its physicochemical properties and in vitro release profile under physiological ocular flow rates, were of key focus. Following optimisation of formulation method conditions such as complexation pH, mode of addition, and charge ratio, the PEC was successfully formulated under mild formulation conditions via polyelectrolyte complexation. With a size of 235.1 ± 19.0 nm, a PDI value of 0.214 ± 0.140, and a zeta potential value of - 38.0 ± 1.1 mV, the chosen PEC, loaded with 430 µg of NAD+ per mg of PEC, exhibited non-Fickian, sustained release at physiological flowrates of 10.9 ± 0.2 mg of NAD+ over 14 h. PECs containing up to 200 µM of NAD+ did not induce any significant cytotoxic effects on an immortalised human corneal epithelial cell line. Using fluorescent labeling, the NAD+-associated PECs demonstrated retention within the corneal epithelium layer of a porcine model up to 6 h post incubation under physiological conditions. A study of the physicochemical behaviour of the PECs, in terms of size, zeta potential and NAD+ complexation in response to environmental stimuli,highlighted the dynamic nature of the PEC matrix and its dependence on both pH and ionic condition. Considering the successful formation of reproducible NAD+-associated PECs with suitable characteristics for ocular drug delivery via an inexpensive formulation method, they provide a promising platform for NAD+ ocular delivery with a strong potential to improve ocular health.
Asunto(s)
Ácido Hialurónico , NAD , Humanos , Animales , Porcinos , Polielectrolitos/química , Polilisina , Sistemas de Liberación de MedicamentosRESUMEN
In this work, living/controlled radical polymerization (LRP) is compared with conventional free radical polymerization in the creation of highly and weakly cross-linked imprinted poly(methacrylic acid-co-ethylene glycol dimethacrylate) networks. It elucidates, for the first time, the effect of LRP on the chain level and begins to explain why the efficiency of the imprinting process is improved using LRP. Imprinted polymers produced via LRP exhibited significantly higher template affinity and capacity compared with polymers prepared using conventional methods. The use of LRP in the creation of highly cross-linked imprinted polymers resulted in a fourfold increase in binding capacity without a decrease in affinity; whereas weakly cross-linked gels demonstrated a nearly threefold increase in binding capacity at equivalent affinity when LRP was used. In addition, by adjusting the double bond conversion, we can choose to increase either the capacity or the affinity in highly cross-linked imprinted polymers, thus allowing the creation of imprinted polymers with tailorable binding parameters. Using free radical polymerization in the creation of polymer chains, as the template-monomer ratio increased, the average molecular weight of the polymer chains decreased despite a slight increase in the double bond conversion. Thus, the polymer chains formed were shorter but greater in number. Using LRP neutralized the effect of the template. The addition of chain transfer agent resulted in slow, uniform, simultaneous chain growth, resulting in the formation of longer more monodisperse chains. Reaction analysis revealed that propagation time was extended threefold in the formation of highly cross-linked polymers when LRP techniques were used. This delayed the transition to the diffusion-controlled stage of the reaction, which in turn led to the observed enhanced binding properties, decreased polydispersity in the chains, and a more homogeneous macromolecular architecture.
Asunto(s)
Radicales Libres/química , Impresión Molecular , Polimerizacion , Acetatos/química , Acetatos/aislamiento & purificación , Adenina/análogos & derivados , Adenina/química , Adenina/aislamiento & purificación , Reactivos de Enlaces Cruzados/química , Disulfiram/química , Disulfiram/aislamiento & purificación , Glicoles de Etileno/síntesis química , Glicoles de Etileno/química , Geles/síntesis química , Geles/química , Cinética , Metacrilatos/síntesis química , Metacrilatos/química , Nitrilos/química , Ácidos Polimetacrílicos/síntesis química , Ácidos Polimetacrílicos/químicaRESUMEN
We have synthesized, characterized, and optimized a novel nano drug-delivery carrier that utilizes the versatile properties of nucleic acid for programmable and on-demand drug release. The drug-delivery carrier consists of 15 nm gold nanoparticles (AuNPs) functionalized with drug binding DNA aptamers via single-stranded (ss) anchor DNA. The presence of anchor DNA makes the nanocarrier flexible to be reprogrammed with various aptamers. Under the optimum binding conditions (0.4 M NaCl and 4 µM DNA), a maximum of 101 ± 8 anchor DNA strands were conjugated per particle. On binding DNA-aptamer:drug complexes to AuNPs, a maximum of 35 neomycin molecules were bound per AuNP. Controlled and extended release of drug from the synthesized carrier was obtained by temperature and affinity modulations. Furthermore, for the first time, we demonstrated that neomycin could bind to DNA with very high affinity (K(d) = 98.101 nM). This DNA-based nanocarrier, designed using the principles of molecular biology, is expected to impact a number of treatment strategies. FROM THE CLINICAL EDITOR: In this basic science work, the authors demonstrate the feasibility of utilizing a novel nano drug-delivery carrier with the versatile properties of nucleic acid for programmable and on-demand drug release.
Asunto(s)
Antibacterianos/administración & dosificación , Aptámeros de Nucleótidos/química , Preparaciones de Acción Retardada/química , Oro/química , Nanopartículas/química , Neomicina/administración & dosificación , Aptámeros de Nucleótidos/metabolismo , Sitios de UniónRESUMEN
Extensive research is currently being conducted into novel ocular drug delivery systems (ODDS) that are capable of surpassing the limitations associated with conventional intraocular anterior and posterior segment treatments. Nanoformulations, including those synthesised from the natural, hydrophilic glycosaminoglycan, hyaluronic acid (HA), have gained significant traction due to their enhanced intraocular permeation, longer retention times, high physiological stability, inherent biocompatibility, and biodegradability. However, conventional nanoformulation preparation methods often require large volumes of organic solvent, chemical cross-linkers, and surfactants, which can pose significant toxicity risks. We present a comprehensive, critical review of the use of HA in the field of ophthalmology and ocular drug delivery, with a discussion of the physicochemical and biological properties of HA that render it a suitable excipient for drug delivery to both the anterior and posterior segments of the eye. The pivotal focus of this review is a discussion of the formation of HA-based nanoparticles via polyelectrolyte complexation, a mild method of preparation driven primarily by electrostatic interaction between opposing polyelectrolytes. To the best of our knowledge, despite the growing number of publications centred around the development of HA-based polyelectrolyte complexes (HA-PECs) for ocular drug delivery, no review articles have been published in this area. This review aims to bridge the identified gap in the literature by (1) reviewing recent advances in the area of HA-PECs for anterior and posterior ODD, (2) describing the mechanism and thermodynamics of polyelectrolyte complexation, and (3) critically evaluating the intrinsic and extrinsic formulation parameters that must be considered when designing HA-PECs for ocular application.
RESUMEN
Purpose: To compare a novel, sustained release formulation and a bolus injection of a targeted nanocarrier for the ability to specifically deplete cells responsible for the development of posterior capsule opacification (PCO) in week-long, dynamic cell cultures. Methods: A novel, injectable, thermosensitive poly(D,L-lactic-co-glycolic acid)-b-poly(ethylene glycol)-b-poly(D,L-lactic-co-glycolic acid) (PLGA-PEG-PLGA) triblock copolymer hydrogel was engineered for the sustained release of targeted, nucleic acid nanocarriers loaded with cytotoxic doxorubicin (G8:3DNA:Dox). Human rhabdomyosarcoma (RD) cells were used due to their expression of brain-specific angiogenesis inhibitor 1 (BAI1), a specific marker for the myofibroblasts responsible for PCO. Under constant media flow, nanocarriers were injected into cell cultures as either a bolus or within the hydrogel. Cells were fixed and stained every other day for 7 days to compare targeted depletion of BAI1+ cells. Results: The formulation transitions to a gel at physiological temperatures, is optically clear, noncytotoxic, and can release G8:3DNA:Dox nanocarriers for up to 4 weeks. In RD cell cultures, G8:3DNA:Dox nanocarriers specifically eliminated BAI1+ cells. The bolus nanocarrier dose showed significantly reduced cell depletion overtime, while the sustained release of nanocarriers showed increased cell depletion over time. By day 7, <2% of BAI1+ cells were depleted by the bolus injection and 74.2% BAI1+ cells were targeted by the sustained release of nanocarriers. Conclusions: The sustained release of nanocarriers from the hydrogel allows for improved therapeutic delivery in a dynamic system. This method can offer a more effective and efficient method of prophylactically treating PCO after cataract surgery.
Asunto(s)
Opacificación Capsular , Hidrogeles , ADN , Preparaciones de Acción Retardada , Doxorrubicina , Humanos , Ácido Láctico , PolietilenglicolesRESUMEN
Since the seminal work of Wichterle in 1965 describing the first soft contact lenses and their potential for ocular drug delivery, the field has yet to realize his vision. Maintaining all lens commercial properties combined with a mechanism for controlled drug release of therapeutically relevant concentrations for duration of wear is a major challenge. Here, successful in vivo week-long sustained release of a small molecular weight therapeutic in rabbits from extended-wear silicone hydrogel contact lenses meeting all commercial specifications by utilizing a novel macromolecular memory strategy is reported for the first time. Lens-treated eyes show a continuous, therapeutically relevant bromfenac tear concentration of 256.4 ± 23.1 µg mL-1 for 8 days. Bromday (bromfenac ophthalmic solution, 0.09%, Bausch+Lomb) topical drops exhibit a quick peak concentration of 269.3 ± 85.7 µg mL-1 and 100 min duration. Bioavailability (AUC0-8days ) and mean residence time of lenses are 26 and 155 times higher than drops, respectively. Lenses are safe, well tolerated, and no corneal histological differences are observed. This work highlights the enormous potential of drug releasing lenses as a platform strategy, and offers a new dropless clinical strategy for post-cataract, uveitis, post-LASIK, and corneal abrasion treatment.
Asunto(s)
Lentes de Contacto de Uso Prolongado , Lentes de Contacto Hidrofílicos , Animales , Córnea , Hidrogel de Polietilenoglicol-Dimetacrilato , Hidrogeles , Conejos , SiliconasRESUMEN
Purpose: This work demonstrates seven-day controlled and extended in vitro physiological flow dual release of multiple post-ocular surgery therapeutics from extended-wear contact lenses as a dropless alternative for treatment of uveitis and corneal inflammation, pain, and infection. Lens replacement each week optimizes treatment matching patient recall time with the ability to increase or decrease dosage. Methods: Lenses were synthesized using molecular imprinting to create lenses with macromolecular memory for diclofenac sodium (DS) and dexamethasone sodium phosphate (DMSP), as well as bromfenac sodium (BS) and moxifloxacin (MOX). Drug uptake and release were analyzed, and physical properties were measured and compared to commercial standards. Results: DS + DMSP-loaded lenses demonstrated seven-days-plus release of each, whereas controls released more than 85% of their payload within the first day. Lenses loaded with BS + MOX demonstrated release of BS and MOX for 11 and eight days, respectively. Structural analysis demonstrated statistically similar mesh size and average molecular weight between crosslinks between imprinted lenses and controls, suggesting that release extension was due to formation of macromolecular memory sites rather than a tighter polymer architecture. Conclusions: Lenses demonstrated in this work have significant clinical applications as an eye drop alternative, possessing the ability to be worn continuously for one week while delivering a consistent amount of therapeutic for the duration of wear. Translational Relevance: In vitro physiological flow release results demonstrate the clinical potential of therapeutic contact lenses as a dropless vehicle for ocular drug delivery.
Asunto(s)
Catarata , Lentes de Contacto Hidrofílicos , Oftalmología , Procedimientos Quirúrgicos Refractivos , Uveítis , Preparaciones de Acción Retardada , Humanos , Hidrogel de Polietilenoglicol-Dimetacrilato , Hidrogeles/uso terapéutico , Siliconas , Uveítis/tratamiento farmacológicoRESUMEN
The novel and unique design of self-assembled micro and nanostructures can be tailored and controlled through the deep understanding of the self-assembly behavior of amphiphilic molecules. The most commonly known amphiphilic molecules are surfactants, phospholipids, and block copolymers. These molecules present a dual attraction in aqueous solutions that lead to the formation of structures like micelles, hydrogels, and liposomes. These structures can respond to external stimuli and can be further modified making them ideal for specific, targeted medical needs and localized drug delivery treatments. Biodegradability, biocompatibility, drug protection, drug bioavailability, and improved patient compliance are among the most important benefits of these self-assembled structures for drug delivery purposes. Furthermore, there are numerous FDA-approved biomaterials with self-assembling properties that can help shorten the approval pathway of efficient platforms, allowing them to reach the therapeutic market faster. This review focuses on providing a thorough description of the current use of self-assembled micelles, hydrogels, and vesicles (polymersomes/liposomes) for the extended and controlled release of therapeutics, with relevant medical applications. FDA-approved polymers, as well as clinically and commercially available nanoplatforms, are described throughout the paper.
RESUMEN
Posterior segment eye diseases (PSEDs) including age macular degeneration (AMD) and diabetic retinopathy (DR) are amongst the major causes of irreversible blindness worldwide. Due to the numerous barriers encountered, highly invasive intravitreal (IVT) injections represent the primary route to deliver drugs to the posterior eye tissues. Thus, the potential of a more patient friendly topical route has been widely investigated. Mucoadhesive formulations can decrease precorneal clearance while prolonging precorneal residence. Thus, they are expected to enhance the chances of adherence to corneal and conjunctival surfaces and as such, enable increased delivery to the posterior eye segment. Among the mucoadhesive polymers available, chitosan is the most widely explored due to its outstanding mucoadhesive characteristics. In this review, the major PSEDs, their treatments, barriers to topical delivery, and routes of topical drug absorption to the posterior eye are presented. To enable the successful design of mucoadhesive ophthalmic drug delivery systems (DDSs), an overview of mucoadhesion, its theory, characterization, and considerations for ocular mucoadhesion is given. Furthermore, chitosan-based DDs that have been explored to promote topical drug delivery to the posterior eye segment are reviewed. Finally, challenges of successful preclinical to clinical translation of these DDSs for posterior eye drug delivery are discussed.
RESUMEN
Purpose: Cataracts are the leading cause of blindness worldwide, resulting in over 30 million surgeries each year. These cases are expected to double within the next 10 years. About 25% of all patients develop secondary cataracts or posterior capsule opacification (PCO) postsurgery. PCO is a vision impairment disorder that develops from myofibroblasts migration and contraction that deforms the capsule surrounding the lens. Currently, Nd:YAG laser therapy is used to treat PCO; however, laser is not available worldwide and adverse side effects may arise. Thus, there is a considerable unmet need for more efficacious and convenient preventive treatments for PCO. Our work focuses on engineering an innovative, prophylactic sustained release platform for DNA-based nanocarriers to further reduce the incidence of PCO. Methods: Novel, optically clear, self-assembled poly(d,l-lactic-co-glycolic acid)-b-poly(ethylene glycol) (PLGA-PEG) triblock copolymer hydrogels were used for the sustained release of the DNA-based nanocarriers (3DNA®) loaded with cytotoxic doxorubicin (DOX) and targeted with a monoclonal antibody called G8 (3DNA:DOX:G8), which is specific to cells responsible for PCO. Results: The 29 (w/v)% polymer hydrogels with the 3DNA nanocarriers presented over 80% of light transmittance, soft mechanical properties (<350 Pa), and sustained release for 1 month. Conclusions: In this work, we show for the first time that the hydrophobic PLGA-PEG-PLGA hydrogels can be used as platforms for sustained delivery of nucleic acid-based nanocarriers. This work demonstrates that polymeric formulations can be used for the extended delivery of ocular therapeutics and other macromolecules to treat a variety of ocular conditions.
Asunto(s)
Antibióticos Antineoplásicos/farmacocinética , Opacificación Capsular/prevención & control , Doxorrubicina/farmacocinética , Portadores de Fármacos/química , Hidrogeles/química , Nanotecnología/métodos , Polietilenglicoles/química , Poliglactina 910/química , Antibióticos Antineoplásicos/administración & dosificación , Antibióticos Antineoplásicos/uso terapéutico , Opacificación Capsular/epidemiología , Doxorrubicina/administración & dosificación , Doxorrubicina/uso terapéutico , Portadores de Fármacos/metabolismo , Sistemas de Liberación de Medicamentos/métodos , Humanos , Incidencia , Micelas , Polietilenglicoles/metabolismo , Poliglactina 910/metabolismoRESUMEN
Biohybrid platforms such as synthetic polymer networks engineered from artificial and natural materials hold immense potential as drug and gene delivery vehicles. Here, we report the synthesis and characterization of novel polymer networks that release oligonucleotide sequences via enzymatic and physical triggers. Chemical monomers and acrylated oligonucleotides were copolymerized into networks, and phosphoimaging revealed that 70% of the oligonucleotides were incorporated into the networks. We observed that the immobilized oligonucleotides were readily cleaved when the networks were incubated with the type II restriction enzyme BamHI. The diffusion of the cleaved fragments through the macromolecular chains resulted in relatively constant release profiles very close to zero-order. To our knowledge, this is the first study which harnesses the sequence-specificity of restriction endonucleases as triggering agents for the cleavage and release of oligonucleotide sequences from a synthetic polymer network. The polymer networks exhibited an oligonucleotide diffusion coefficient of 5.6 x 10(-8) cm(2)/s and a diffusional exponent of 0.92. Sigmoidal temperature responsive characteristics of the networks matched the theoretical melting temperature of the oligonucleotides and indicated a cooperative melting transition of the oligonucleotides. The networks were also triggered to release a RNA-cleaving deoxyribozyme, which degraded a HIV-1 mRNA transcript in vitro. To tailor release profiles of the oligonucleotides, we controlled the structure of the macromolecular architecture of the networks by varying their cross-linking content. When incubated with DNase I, networks of cross-linking content 0.15%, 0.22%, and 0.45% exhibited oligonucleotide diffusion coefficients of 1.67 x 10(-8), 7.65 x 10(-9), and 2.7 x 10(-9) cm(2)/s, and diffusional exponents of 0.55, 0.8, and 0.8, respectively. The modular nature of our platform promises to open new avenues for the creation and optimization of a rich toolbox of novel drug and gene delivery platforms. We anticipate further inquiry into nucleic acid based programmable on-demand switches and modulatory devices of exquisite sensitivity and control.
Asunto(s)
Sistemas de Liberación de Medicamentos/métodos , Oligonucleótidos/metabolismo , Oligonucleótidos/uso terapéutico , Reactivos de Enlaces Cruzados , ADN Catalítico/metabolismo , Desoxirribonucleasa BamHI/metabolismo , Desoxirribonucleasa I/metabolismo , VIH-1/genética , Humanos , Oligonucleótidos/administración & dosificación , Polímeros/síntesis química , Profármacos/síntesis química , ARN Viral/metabolismo , ARN Viral/uso terapéuticoRESUMEN
Molecular imprinting techniques have been developed for the preparation of biomimetic polymer networks that can recognize a general moiety, D-glucose, and the novel evaluation of loading and release of a larger molecule with glucose as an integral part of its structure [i.e., fluorescently tagged glucose (2-(N-(7-nitrobenz-2-oxa-1,3-diazol-4-yl)amino)-2-deoxy-glucose) or 2-NBDG]. Poly(acrylamide-co-poly(ethylene glycol)dimethacrylate) networks with varying crosslinking monomer percentages (80, 67, and 30%) and crosslinker lengths (average number of ethylene glycol units of 1, 4, and 14) were prepared and characterized using a novel fluorescent microscopy technique, which allowed for microscale observation of the dynamic binding and release of 2-NBDG within the polymer film. Experimental results indicate that tighter mesh-sized networks had increased affinity and capacity towards the glucose functionalized molecule as well as increased diffusional transport times, indicating the strong potential to load significantly higher amounts of therapeutic within intelligent carriers as well as control and extend the rate of release via macromolecular structure.
Asunto(s)
Materiales Biomiméticos/química , Sistemas de Liberación de Medicamentos , Impresión Molecular , 4-Cloro-7-nitrobenzofurazano/análogos & derivados , 4-Cloro-7-nitrobenzofurazano/química , Reactivos de Enlaces Cruzados/química , Desoxiglucosa/análogos & derivados , Desoxiglucosa/química , Difusión , Estructura MolecularRESUMEN
Molecular imprinting provides a rational design strategy for the development of controlled release drug delivery systems. We demonstrate that imprinting a hydrogel network results in macromolecular memory for the template molecule, indicated by the two or more times greater partitioning into these networks as compared to non-imprinted networks. Partitioning of drug into networks synthesized from multiple functional monomers was 8 times greater than networks synthesized from single monomers. One-dimensional permeation studies showed that the gel with maximum incorporated chemical functionality had the lowest diffusion coefficient, which was one to two orders of magnitude lower than all other gels studied. All imprinted networks had significantly lower diffusion coefficients than non-imprinted networks, in spite of comparable mesh sizes and equilibrium polymer volume fractions in the swollen state, which to our knowledge, is the first time that such a study has been conducted in the literature. We propose the "tumbling hypothesis", wherein a molecule tumbling through an imprinted network with multiple, organized functionalities and an appropriate mesh size, experiences heightened interactions with memory sites and shows delayed transport kinetics. Thus, the structural plasticity of polymer chains, i.e. the organization of functional groups into memory sites, may be responsible for enhanced loading and extended release.
Asunto(s)
Preparaciones de Acción Retardada/química , Hidrogeles/química , Impresión Molecular/métodos , Algoritmos , Biomimética , Reactivos de Enlaces Cruzados , Difusión , Diseño de Fármacos , Antagonistas de los Receptores Histamínicos H1/administración & dosificación , Antagonistas de los Receptores Histamínicos H1/química , Indicadores y Reactivos , Cetotifen/administración & dosificación , Cetotifen/química , Vehículos Farmacéuticos , Polietilenglicoles , Polihidroxietil MetacrilatoRESUMEN
In the past decade, there has been an exponential increase in the number of papers describing molecular imprinting in hydrogels, a technique which creates memory for template molecules within a flexible macromolecular structure. Macromolecular memory or structural plasticity of polymer chains is a superior description of weakly crosslinked imprinted networks since significant flexibility can occur within the polymer chains. The focus of this article is to review and highlight work in the field describing the imprinting strategy within hydrogels and associated challenges, characterization methods of imprinted gels, current and potential translational applications, and future strategies and directions. This paper also describes ways to improve binding parameter efficacy and presents significant areas of opportunity to further describe, characterize, and understand imprinted gels. An analysis of the literature indicates that imprinting in hydrogels leads to significant improvements in template affinity, capacity, and selectivity over non-templated hydrogels for a number of templates such as ions, small and moderate molecular weight molecules, proteins, viruses, DNA, and cells. However, the influence of imprinting on the transport of template is much more complex, with little attention of most studies to structural analysis or discussion of the gel porosity/tortuosity in the control of template transport. Responsive, intelligent imprinted hydrogels are also highlighted that exhibit reversibly modulated template binding and transport. It is clear that this field has transitioned from infancy and is leading to breakthroughs in a number of areas such as controlled and modulated drug delivery, diagnostic sensors, and separation. For example in drug delivery, imprinting can lead to delayed transport and provides further control of therapeutic transport through the macromolecular structure as well as optimizes the number of therapeutic molecules to polymer chains.
Asunto(s)
Portadores de Fármacos/química , Hidrogeles/química , Impresión Molecular/métodos , Transporte Biológico , Química Farmacéutica/métodos , Preparaciones de Acción Retardada , Sistemas de Liberación de Medicamentos , Preparaciones Farmacéuticas/química , Preparaciones Farmacéuticas/metabolismo , Polímeros/química , Tecnología Farmacéutica/métodosRESUMEN
We have applied the principles of biomimesis by incorporating a natural receptor-based rational design strategy in the synthesis of novel recognitive soft contact lenses. We have demonstrated the potential of biomimetic carriers to load significant amounts of ocular medication such as H(1)-antihistamines, as well as to release a therapeutic dosage of drug in vitro in a controlled fashion for 5 days, with an even further extension in the presence of protein. Gels of multiple complexation points with varying functionalities outperformed gels formed with less diverse functional monomers and showed superior loading with a six-fold difference over control gels and a three-fold difference over less biomimetic gels. Moreover, mechanical and optical properties of these hydrogels agreed with conventional lenses, and increased loading was reflected in a reduced propagation of polymer chains. This approach can be extended to a wider biological spectrum in the design of novel, controlled and modulated delivery devices to alleviate ocular disorders and provide an alternative to topical therapy.
Asunto(s)
Materiales Biomiméticos/química , Lentes de Contacto , Portadores de Fármacos/química , Oftalmopatías/terapia , Hidrogeles/química , Materiales Biomiméticos/síntesis química , Portadores de Fármacos/síntesis química , Hidrogeles/síntesis química , CinéticaRESUMEN
Approximately 1 in 5000-8000 children are born annually with a lysosomal storage disease (LSD), which affects their cells' ability to break down naturally occurring substrates. Accumulation, or "storage," of undegraded substrates leads to a wide variety of clinical symptoms, and early mortality. Currently, for LSDs with central nervous system (CNS) involvement, there is no available treatment. Four methods of treatment are being explored in clinical trials and preclinical settings: enzyme replacement therapy, ex vivo gene therapy, in vivo gene therapy, and nanoparticle-based therapy. In general, each therapeutic approach has been hindered by an inability to cross the blood-brain barrier (BBB) without invasive intracranial surgeries. Also, once the treatment has entered the brain, it is difficult to ensure therapeutic levels of enzyme distributed evenly throughout the entire parenchyma. Enzyme replacement therapy (ERT) is the current standard of care for lysosomal diseases without CNS involvement. However, with the recent advent of nanoparticle-based therapy, direct targeting of either gene therapy or ERT to the brain has become plausible. Ex vivo gene therapy, in vivo gene therapy, ERT and nanoparticle-based therapies are explained, while synthesizing and analyzing their potential as clinical treatments targeted to the CNS. While difficulties in treating the entire brain remain, preclinical studies demonstrate profound therapeutic benefit in animal models and generate hope for successful translation to humans.